Loading ...
Sorry, an error occurred while loading the content.

Nanogen news today

Expand Messages
  • Al
    Imo this was some really BIG TIME news! Press Release Source: Nanogen, Inc. Nanogen Issued Nanotechnology Patent for Photonic Driven Assembly and Hybridization
    Message 1 of 1 , Mar 18, 2004
    • 0 Attachment
      Imo this was some really BIG TIME news!




      Press Release Source: Nanogen, Inc.


      Nanogen Issued Nanotechnology Patent for Photonic Driven Assembly
      and Hybridization
      Thursday March 18, 8:01 am ET


      SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:
      NGEN - News) announced today that it was issued U.S. Patent No.
      6,706,473, "Systems and Devices for Photoelectrophoretic Transport
      and Hybridization of Oligonucleotides," by the U.S. Patent and
      Trademark Office. The '473 patent relates to new devices for
      nanofabrication that enable the photoelectric transport and
      positioning of self-assembling DNA nanostructures (and
      microstructures) on a semiconductor substrate material. These
      devices use directed light beams to create precise electric fields
      on the substrate material. Charged nanostructures (such as DNA
      derivatized nanoparticles) are transported to the electric field
      site where they become attached and can then lead to the further
      self-organization of higher-order nanoscale or microscale structures
      and devices. With the addition of the '473 patent, Nanogen now has
      58 issued patents in the United States.
      "The '473 patent builds upon our previous nanotechnology patents by
      describing nanofabrication and assembly approaches using photonics
      to create guiding electronic fields," said Howard C. Birndorf,
      Nanogen chairman and chief executive officer. "This technology would
      allow us or others to create very small scale electronic arrays
      where the addressable fields are independent of preset platform
      designs and could greatly increase the flexibility of manufacturing
      and use of electronic arrays."

      "More broadly, the '473 patent represents a potential manufacturing
      technology that combines the best aspects of self-assembly and
      microfabrication processes for the nanofabrication of 2D and 3D
      structures and devices. This highly parallel process has the
      inherent hierarchical logic to control the organization, assembly
      and communication of structures and components ranging in size from
      the molecular scale through macroscale systems," said Dr. Michael J.
      Heller, co-founder of Nanogen, and currently a professor in the
      Departments of Bioengineering and Electrical and Computer
      Engineering at the University of California, San Diego.

      In addition to the creation of selectively addressable DNA
      electronic array substrates and materials, the technology described
      in the '473 patent could have numerous applications including:

      (1) Creation of molecular-based electronic and photonic
      mechanisms,
      materials and devices;
      (2) Organization, assembly and interconnection of multiple
      scale
      components (from nanostructures to microcomponents) onto
      silicon
      materials and also, potentially, within the perimeters of
      microelectronic and optoelectronic structures on the
      silicon
      substrate;
      (3) Production of multiple layer nanocomposite materials;
      (4) Creation and manufacturing of novel photonic and
      electronic devices
      such as high-density 2D and 3D data storage materials and
      devices or
      photonic crystal structures;
      (5) Development of low density optical memory for applications
      in
      authentication, anti-counterfeiting, and encryption of
      information
      in document or goods; and
      (6) Heterogeneous integration of hybrid devices such as large
      area light
      emitting flat panel arrays, displays and medical
      diagnostic devices
      with the fabrication platform itself becoming the final
      product
      (such as a flat panel array or display screen).


      About Nanogen

      Nanogen, Inc. develops and commercializes products for the in vitro
      diagnostics market. The company seeks to establish the unique, open-
      architecture NanoChip® Molecular Biology Workstation and NanoChip®
      Cartridge as the standard platform for the prediction, diagnosis and
      treatment of genetic and infectious diseases. Nanogen also offers
      Analyte Specific Reagents and related products to research and
      clinical reference labs for the detection of a variety of diseases,
      such as cystic fibrosis, Alzheimer's disease, and cardiovascular
      disease. The company is advancing its nanotechnology research to
      further its mission of delivering advanced diagnostic products to
      physicians and patients. For additional information please visit
      Nanogen's website at www.nanogen.com.

      Forward-Looking Statement

      This press release contains forward-looking statements that are
      subject to risks and uncertainties that could cause actual results
      to differ materially from those set forth in the forward-looking
      statements, including whether patents owned or licensed by Nanogen
      will be developed into products, whether Nanogen's NanoChip® System
      can be successfully further commercialized, whether other products
      under development can be successfully developed and commercialized,
      whether results reported by our customers or partners can be
      identically replicated, whether ASRs currently sold by Nanogen will
      become FDA-approved molecular diagnostic test kits, whether Nanogen
      will be successful in developing additional ASRs and protocols
      utilizing the NanoChip® System, and other risks and uncertainties
      discussed under the caption "Factors That May Affect Results" and
      elsewhere in Nanogen's Form 10-K for the year ended December 31,
      2002 filed with the Securities and Exchange Commission. These
      forward-looking statements speak only as of the date hereof. Nanogen
      disclaims any intent or obligation to update these forward-looking
      statements.




      ---------------------------------------------------------------------
      -----------
      Source: Nanogen, Inc.
    Your message has been successfully submitted and would be delivered to recipients shortly.